AAT-AD/PD™ in the News

Articles about research presented at the the AAT-AD/PD™ 2020 Entirely Virtual Meeting.

“AXON Neuroscience SE (“Axon”) an industry leading, clinical stage biotech company at the forefront of treating and preventing Alzheimer’s Disease, presented the positive results of its Phase II trial for AADvac1, the first tau vaccine to treat and prevent Alzheimer’s Disease, at the AAT-AD/PD 2020 conference.”

“The research presented at AAT-AD/PD investigates changes induced by P. gingivalis at the cellular level. The data shows the expression of P. gingivalis and gingipains inside of co-cultured brain cells after infection, including neurons, astrocytes, and microglial cells and the display of cellular pathology consistent with AD.”

” Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and neurodegenerative diseases, today announced that the company’s vice president of preclinical research, Elizabeth Evans, Ph.D, delivered a virtual presentation at the Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020″

“Kenes Group’s medical conference, The 2nd AAT-AD/PD Focus Meeting 2020, takes off successfully with an innovative mindset”

“It is incredible what the organizers managed to do in such a short time span, providing a platform for sharing progress in therapeutic development for AD and Parkinson’s disease so that this vital research can move forward despite the circumstances.”

“At AAT-ADPD, researchers report how they built on prior reports that a person’s blood level of p-tau181 tells if they have Alzheimer’s.”

“P-tau217 appears sooner than p-tau181 in the brain, and it distinguishes AD from controls and other dementias even more cleanly.”

“Data shown at AAT-AD/PD explain why the DIAN-TU trial missed its primary endpoint. But gantenerumab strongly reduced plaques, tau, phospho-tau, and slowed NfL. This result prompted an open-label extension, sustaining hope for efficacy.”

“At the virtual AAT-AD/PD Focus meeting held April 1 to 5, clinicians and funders involved in the Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) fired up their home computers to discuss results from the first DIAN-TU treatment and prevention trial of Eli Lilly’s monoclonal antibody solanezumab, and Roche’s gantenerumab.”

In a Phase 2 trial, the vaccine reportedly normalized the rise in plasma NfL, and appeared to lower CSF tau and retard brain atrophy.

“Researchers at the online AAT-AD/PD meeting touted therapies that target neuroinflammation, synapses, epigenetic regulation, or the cortisol stress response.”

“In people with Alzheimer’s biomarkers, the basal forebrain shrinks early, foreshadowing microglial neurotoxicity, atrophy in the medial temporal lobe, and cognitive decline.”

“Scientists report at AAT-AD/PD that they tightened a causal connection between gut microbes, microglial function, and protein deposits. In mice, that is.”

“For people with Parkinson’s, carrying Alzheimer’s risk variants upped their odds of harboring Aβ and tau pathology and getting dementia. In people with DLB, Aβ plaques worsened tau and Lewy pathology, and cognition.

“In a mouse model of amyloidosis, human wild-type TREM2 kept Aβ deposition at bay early on, but this defense became overwhelmed as plaques grew. The R47H AD risk variant never offered protection early on, and made things worse later.”

“Trialists are shooting new arrows at the disease, including compounds that tweak neuroinflammation, autophagy, and membrane glycolipid recycling.”

“The first topline Phase 2 results from an antibody targeting Parkinson’s pathology, Roche’s prasinezumab, were a mixed bag. Next steps are unclear.”